26 Jan 2023 by admin in UncategorizedComments Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome
20 Dec 2022 by admin in UncategorizedComments 科越医药宣布在中国和澳大利亚启动 KP104 在 IgA 肾病(IgAN)和 C3 肾小球病 (C3G)的 II 期临床试验
09 Dec 2022 by admin in UncategorizedComments Arcellx And Kite Announce Strategic Collaboration To Co- Develop And Co-Commercialize Late-Stage Clinical CART- DdBCMA In Multiple Myeloma
02 Dec 2022 by admin in UncategorizedComments 健新原力全新 GMP 生产基地&公司总部大楼(中国，杭州)投入 运营，进一步为全球客户提供 RNA、细胞和基因疗法的 CDMO 一 站式服务
30 Nov 2022 by admin in UncategorizedComments 科越医药宣布 KP104 用于治疗阵发性睡眠性血红蛋白尿症(PNH)的 II 期临床 首个队 列的患者已完成第一次给药
30 Nov 2022 by admin in UncategorizedComments Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer
17 Nov 2022 by admin in UncategorizedComments Laronde Appoints Pablo J. Cagnoni as Chief Executive Officer
15 Nov 2022 by admin in UncategorizedComments NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates
14 Nov 2022 by admin in UncategorizedComments Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
14 Nov 2022 by admin in UncategorizedComments Arcellx Reports Third Quarter 2022 Financial Results And Business Progress
08 Nov 2022 by admin in UncategorizedComments Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update
08 Nov 2022 by admin in UncategorizedComments Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates
07 Nov 2022 by admin in UncategorizedComments Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics
03 Nov 2022 by admin in UncategorizedComments NextCure Provides Update and Reports Third Quarter 2022 Financial Results
03 Nov 2022 by admin in UncategorizedComments Kira Pharmaceuticals Presents Complete Data from Phase 1 SYNERGY-1 Trial of KP104 at American Society for Nephrology Kidney Week 2022
03 Nov 2022 by admin in UncategorizedComments Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
27 Oct 2022 by admin in UncategorizedComments NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board
17 Oct 2022 by admin in UncategorizedComments 科越医药宣布 KP104 用于治疗阵发性睡眠性血红蛋白尿症(PNH)的 II 期 临床试验申请 已获得中国国家药品监督管理局批准
03 Oct 2022 by admin in UncategorizedComments 科越医药 KP104 治疗系统性红斑狼疮相关血栓性微血管病(SLE-TMA)的 II 期临床试 验申请获得美国 FDA 批准
16 Sep 2022 by admin in UncategorizedComments Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement
15 Sep 2022 by admin in UncategorizedComments Syros and Tyme Technologies Announce Stockholder Approval of Merger
15 Aug 2022 by admin in UncategorizedComments Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates
08 Aug 2022 by admin in UncategorizedComments Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results
04 Aug 2022 by admin in UncategorizedComments NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results
04 Aug 2022 by admin in UncategorizedComments Laronde Appoints John Mendlein as Chief Executive Officer
03 Aug 2022 by admin in UncategorizedComments Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS
01 Aug 2022 by admin in UncategorizedComments Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease
28 Jul 2022 by admin in UncategorizedComments KIRA PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR KP104, A BIFUNCTIONAL ANTIBODY FUSION PROTEIN, FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
06 Jul 2022 by admin in UncategorizedComments Crescendo Biologics announces nomination of second proprietary clinical candidate from immuno-oncology Humabody VH development portfolio
06 Jul 2022 by admin in UncategorizedComments NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec- 15-positive Tumors as reported in Laboratory Investigation
05 Jul 2022 by admin in UncategorizedComments Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
22 Jun 2022 by admin in UncategorizedComments Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annua
